SANTA MONICA, Calif. – GoodRx has announced that the new higher dose Wegovy HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.
“Pharmaceutical innovation is moving quickly to meet the evolving needs of patients, and access has to keep pace,” said Wendy Barnes, president & CEO at GoodRx. “Wegovy HD is a strong example of how manufacturers are expanding options to support patients at different stages of treatment. GoodRx is proud to help translate that innovation into real-world access, connecting patients to the FDA-approved therapies and dosing they need with clear, predictable pricing.”
As demand for GLP-1 treatments continues to grow, many consumers are navigating access outside of traditional insurance coverage. GoodRx simplifies that experience by surfacing upfront pricing and connecting it directly to nationwide pharmacy access, helping consumers understand their options before they reach the pharmacy counter.
“We’re continuing to expand the Wegovy® portfolio with a simple goal: give patients the right option at the right time in their treatment,” said Ed Cinca senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Wegovy® HD adds another FDA-approved option to meet patients’ clinical needs. Working with GoodRx helps make these medicines easier to access for the people who need them.”
For those who need help getting started, GoodRx for Weight Loss offers a connected path to care. Through the subscription service, consumers can meet with licensed healthcare providers, complete an eligibility assessment, and, when appropriate, receive a prescription for FDA-approved GLP-1 treatments.
This announcement builds on GoodRx’s ongoing efforts to expand access to GLP-1 medications, reflecting a broader shift toward self-pay models that provide more predictable and transparent pathways to treatment. GoodRx enables these programs to reach consumers at scale, helping ensure that pricing translates into real-world access from day-one.
